Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
about
Screening for nasopharyngeal cancerReal-time PCR in clinical microbiology: applications for routine laboratory testing.Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for fieCurrent management strategy of nasopharyngeal carcinoma.Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor originPositivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.Laboratory assays for Epstein-Barr virus-related disease.A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma.Emerging biomarkers in head and neck cancer in the era of genomics.Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer.Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma.Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma.Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan.Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs.Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States.MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign Hyperplasia.The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma.
P2860
Q24187937-F2C2990D-8AC2-456D-B426-FA91DBFC9965Q27472851-85D94793-4819-46B2-9534-35AB5095C02EQ33239049-56A2E4D8-1A98-4F69-B379-00A63DBE7DB0Q33764579-1609AFC7-E189-499B-ADBD-C96C8DA2E422Q35619542-6D99CACB-2361-48A4-9DBE-EC4D8EDD9097Q36124331-FE7000AC-AE5C-4D54-A8D2-AE9C2EE69E40Q36305182-EC6D1C59-65B2-404E-BE2F-5DF7CD754D26Q37086039-FFF70225-5B66-4BB7-B0E0-41372C091C4EQ37192117-83589EC5-D601-41E0-8351-DBFD0F292A0AQ38172510-5EF6429D-23F5-4071-9D54-8B16F06CF961Q38268896-A73E4FCC-0753-455B-A349-D9EB903A7144Q38270678-C017226E-787C-4B1E-8E92-4EF080408812Q38735125-B344B997-BF29-4E42-A7D9-5F0C3AE7CDB8Q40163936-68A45E6A-42FF-417D-8FAE-98310A73AD7EQ41035366-C698D7F2-7CEB-4415-9BAB-BB9D1ACECA4CQ42239637-0B6F436D-C7DC-4992-A3A1-9CCF56256259Q42256571-E4C28A88-2297-434C-BD26-5A19523F43D4Q43063274-0002AD31-DFAF-4296-95E0-4F954851F51CQ43941355-6B74F2A3-D782-41BF-90C7-49564ECE89D5Q44554229-A5991D40-3E44-4E67-9D2D-238D385736F2Q44833814-D374AD97-8C15-4C13-8E95-6B1C8EFE6234Q45403303-973E2917-7B41-4005-B46B-C0E979CE8169Q48334944-92B21B00-3C4A-4038-A23F-4BBB7C88FA73Q54254993-5612BE56-B5D3-4D80-8D8E-23DCE4013C78
P2860
Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@en
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@nl
type
label
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@en
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@nl
prefLabel
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@en
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@nl
P2093
P1433
P1476
Improved accuracy of detection ...... l capsid antigen IgA antibody.
@en
P2093
Andrew Van Hasselt
Anthony T C Chan
Dolly P Huang
John S Tam
Lisa Y S Chan
Philip J Johnson
Sing-Fai Leung
Y M Dennis Lo
P304
P356
10.1373/CLINCHEM.2003.022426
P407
P577
2003-12-18T00:00:00Z